Methotrexate and allergy medication is a combination that requires careful consideration, as some commonly used allergy remedies can interact with methotrexate in clinically significant ways. Methotrexate is a widely prescribed DMARD and immunosuppressant used in the UK for rheumatoid arthritis, psoriasis, and other inflammatory conditions. Because it has a narrow therapeutic window and is primarily cleared by the kidneys, even over-the-counter allergy products can affect its safety profile. This article explains which allergy medications are generally safe alongside methotrexate, which carry serious risks, and what UK guidance from NICE and the MHRA recommends for patients managing both conditions.

How Methotrexate Works and Why Interactions Matter

Methotrexate is renally eliminated and has a narrow therapeutic window, meaning drugs that impair renal clearance — such as NSAIDs — can significantly raise plasma concentrations and increase toxicity risk.

Methotrexate is a disease-modifying antirheumatic drug (DMARD) and immunosuppressant used widely in the UK to treat conditions including rheumatoid arthritis, psoriasis, psoriatic arthritis, and certain inflammatory conditions. It works primarily by inhibiting dihydrofolate reductase (DHFR), an enzyme essential for DNA synthesis and cell replication. At the lower doses used in rheumatology and dermatology, however, its anti-inflammatory effect is thought to be driven largely by a separate mechanism — the accumulation of adenosine via inhibition of AICAR transformylase — rather than direct cytotoxicity. This distinction helps explain why methotrexate acts as an immunomodulator at these doses rather than a conventional chemotherapy agent.

Methotrexate is eliminated predominantly unchanged by the kidneys, with only minor hepatic metabolism. This means that any condition or medication that impairs renal clearance can significantly raise methotrexate plasma concentrations, increasing the risk of toxicity. Patients with pre-existing renal impairment are at particular risk and require closer monitoring.

Because of this narrow therapeutic window and primary renal elimination, a number of commonly used medicines can interact with methotrexate in clinically important ways. Key examples include NSAIDs (which reduce renal clearance), trimethoprim and co-trimoxazole (which inhibit folate metabolism and can cause severe haematological toxicity), some penicillins (which compete for renal tubular secretion), and proton pump inhibitors (PPIs), which may reduce methotrexate clearance. Patients should always seek advice from their GP or pharmacist before starting any new medicine — including over-the-counter products — while taking methotrexate.

Allergy symptoms are extremely common, and many patients taking methotrexate will at some point seek relief from hay fever, urticaria, or other allergic conditions. Understanding which allergy medications are safe to use alongside methotrexate is therefore both clinically important and frequently encountered in practice.

Common Allergy Medications and Their Risks With Methotrexate

Systemic corticosteroids and NSAIDs carry the greatest interaction risk with methotrexate; intranasal decongestants, ocular preparations, and leukotriene receptor antagonists such as montelukast are generally low risk.

Allergy medications span several drug classes, each carrying a different risk profile when used alongside methotrexate. The most commonly used include:

• Antihistamines (e.g., cetirizine, loratadine, chlorphenamine)

• Intranasal and topical corticosteroids (e.g., fluticasone, beclometasone)

• Systemic corticosteroids (e.g., prednisolone)

• Nasal decongestants (e.g., xylometazoline nasal spray, pseudoephedrine)

• Leukotriene receptor antagonists (e.g., montelukast)

• Ocular preparations (e.g., sodium cromoglicate eye drops, olopatadine eye drops)

Of these, systemic corticosteroids require the most careful consideration. There is no direct pharmacokinetic interaction between prednisolone and methotrexate, but their combined use carries an additive risk of serious infection due to cumulative immunosuppression. Systemic steroids can also mask early signs of methotrexate toxicity, such as fever or malaise. Short courses under medical supervision are sometimes used deliberately to manage disease flares, but long-term combined use is generally avoided. There is no established evidence that concurrent use increases the risk of bone marrow suppression or hepatotoxicity beyond the individual risks of each drug.

NSAIDs (such as ibuprofen) are not treatments for allergy itself, but patients may reach for them to relieve associated discomfort. NSAIDs reduce renal clearance of methotrexate, raising plasma concentrations and increasing the risk of toxicity — including mucositis, cytopaenia, and renal impairment. Patients should not self-start NSAIDs while taking methotrexate; occasional use may be considered only under prescriber guidance with appropriate monitoring. It is also important to check the ingredients of combination 'cold and flu' remedies, as many contain ibuprofen or aspirin.

Topical nasal decongestants (e.g., xylometazoline) have minimal systemic absorption and are generally considered low risk when used short term (no more than seven days). Leukotriene receptor antagonists such as montelukast are not known to interact directly with methotrexate. Ocular antihistamines and mast cell stabilisers (e.g., olopatadine, sodium cromoglicate eye drops) have negligible systemic absorption and are suitable low-risk options for eye symptoms.

The key principle is that no over-the-counter allergy remedy should be assumed automatically safe simply because it is available without prescription. Always inform your pharmacist that you are taking methotrexate before purchasing any allergy product.

Antihistamines, Corticosteroids, and Methotrexate: What the Evidence Shows

Second-generation antihistamines and intranasal corticosteroids are generally safe with methotrexate; systemic corticosteroids may be used short term under medical supervision but carry additive immunosuppression risk.

Antihistamines are among the most frequently used allergy medications in the UK. Second-generation antihistamines such as cetirizine and loratadine are generally considered low risk in patients taking methotrexate. There is no established pharmacokinetic interaction between these agents and methotrexate; they do not affect folate metabolism, renal clearance, or hepatic enzyme pathways in a clinically meaningful way. First-generation antihistamines such as chlorphenamine are also unlikely to interact directly with methotrexate, though their sedative properties may compound the fatigue that is a common side effect of methotrexate itself. Patients taking sedating antihistamines should be advised not to drive or operate machinery until they know how the medicine affects them, and to avoid alcohol.

Intranasal corticosteroids, such as fluticasone propionate nasal spray (available over the counter for hay fever), have very low systemic absorption and are widely regarded as safe for use in patients on methotrexate. NICE Clinical Knowledge Summaries (CKS) for allergic rhinitis support their use as a first-line treatment, and their minimal systemic bioavailability means the immunosuppressive interaction risk is negligible in most patients. Similarly, intranasal antihistamine sprays (e.g., azelastine) have low systemic exposure and are a reasonable option.

Ocular preparations including sodium cromoglicate and olopatadine eye drops are suitable for eye symptoms associated with allergic rhinitis. Their systemic absorption is negligible, and no clinically relevant interaction with methotrexate is expected.

Systemic corticosteroids present a more complex picture. There is no direct pharmacokinetic interaction with methotrexate, and no established evidence that concurrent use increases hepatotoxic risk. The primary concern is additive immunosuppression, which raises the risk of serious opportunistic infections, and the potential for systemic steroids to mask early symptoms of methotrexate toxicity. Short courses (for example, a five-day course of prednisolone for a severe allergic reaction) may occasionally be prescribed alongside methotrexate under medical supervision, using the lowest effective dose for the shortest necessary duration. Decisions about systemic steroid use in patients on methotrexate should always involve the supervising specialist or GP.

MHRA and NICE Guidance on Managing Allergies During Treatment

MHRA and NICE recommend patients avoid self-starting NSAIDs, always inform their pharmacist they are taking methotrexate, and use paracetamol for symptomatic relief where appropriate.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued Drug Safety Updates highlighting the risks of methotrexate interactions and dosing errors, including a 2020 update reinforcing that methotrexate must be taken once weekly only, and emphasising the importance of patient education, regular monitoring, and clear communication between prescribers and patients about which medicines are appropriate to use. Methotrexate is subject to a shared care protocol in most NHS trusts, meaning GPs and specialists share responsibility for monitoring and managing the patient's overall medication burden.

NICE guidance on rheumatoid arthritis (NG100) and psoriasis (CG153) recommends that patients on methotrexate receive structured monitoring and clear written information about drug interactions. For allergic rhinitis, NICE CKS recommends intranasal corticosteroids and non-sedating antihistamines as first-line treatments — both of which are generally compatible with methotrexate use.

Patients are encouraged to:

• Always inform their pharmacist that they are taking methotrexate before purchasing any over-the-counter allergy remedy

• Avoid self-starting ibuprofen, aspirin, or any NSAID-containing product for allergy-related symptoms; use only if specifically advised by your prescriber with appropriate monitoring. Note that low-dose aspirin prescribed for cardiovascular protection should be continued unless your doctor advises otherwise

• Use paracetamol as a safer alternative for symptomatic relief where appropriate

• Carry their patient-held methotrexate monitoring record (issued by most NHS trusts) to all consultations, including pharmacy visits — this is separate from the MHRA Yellow Card scheme

• Report suspected side effects from any medicine, including methotrexate, through the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk or via the Yellow Card app)

Patients should also be aware that trimethoprim, co-trimoxazole, and some penicillin antibiotics can interact seriously with methotrexate. If you are prescribed an antibiotic, always tell the prescriber that you are taking methotrexate.

When to Speak to Your GP or Specialist About Allergy Symptoms

Patients should withhold their next methotrexate dose and seek urgent same-day medical advice if they develop new cough, breathlessness, fever, rash, mouth ulcers, or unusual bruising.

Patients taking methotrexate should not assume that allergy symptoms are always straightforward or unrelated to their treatment. Some symptoms that resemble allergic reactions — such as skin rashes, breathlessness, or a dry cough — may in fact be adverse effects of methotrexate itself. Methotrexate-induced pneumonitis, for example, can present with cough, breathlessness, and fever, and may be mistaken for a respiratory allergy or infection. This is a potentially serious complication that requires prompt medical assessment.

If you develop any of the following symptoms, withhold your next dose of methotrexate and seek urgent same-day medical advice — contact your GP, specialist, or NHS 111 if your GP is not immediately available:

• A new or worsening cough, shortness of breath, or chest tightness

• Fever, chills, or signs of infection

• A skin rash that is spreading, blistering, or accompanied by fever

• Mouth ulcers or soreness

• Unusual bruising or bleeding

• Severe sore throat

• Jaundice (yellowing of the skin or whites of the eyes) or dark urine

• Symptoms that do not respond to standard allergy treatments within a few days

• Any allergic reaction after starting a new medication

Do not stop methotrexate permanently without medical advice, as abrupt discontinuation can cause a flare of the underlying condition. However, withholding a single dose while awaiting urgent assessment is appropriate if serious toxicity is suspected.

If you experience a severe allergic reaction (anaphylaxis) — including throat swelling, difficulty breathing, or collapse — call 999 immediately, as this is a medical emergency regardless of your current medications.

Monitoring and Staying Safe While Taking Methotrexate

Regular blood monitoring — full blood count, liver function, and renal function — every one to three months is essential, alongside folic acid supplementation and avoiding live vaccines.

Safe use of methotrexate depends heavily on regular monitoring. In line with NICE, MHRA, and British Society for Rheumatology (BSR) recommendations, patients starting methotrexate or having their dose increased should have blood tests — typically a full blood count, liver function tests, and renal function — every one to two weeks for the first six weeks, then monthly until the dose is stable, and thereafter every two to three months. These tests help detect early signs of toxicity, including bone marrow suppression and liver changes, which can be worsened by interacting medications.

Folic acid supplementation (usually 5 mg once weekly, taken on a different day to methotrexate) is routinely prescribed alongside methotrexate to reduce the risk of folate-related side effects such as mucositis and nausea. Continue taking folic acid as prescribed, particularly if you are also using any medication that might affect folate metabolism.

Vaccination: Patients on methotrexate should avoid live vaccines (such as MMR, yellow fever, and live attenuated influenza vaccine). Inactivated vaccines — including annual influenza vaccine and COVID-19 vaccines — are recommended and safe. Discuss your vaccination status with your GP or specialist.

To stay safe while managing allergy symptoms on methotrexate, consider the following practical steps:

• Keep an up-to-date medication list and share it with every healthcare professional you see, including dentists and pharmacists

• Use your patient-held methotrexate monitoring record to document all medications, including over-the-counter products

• Opt for intranasal corticosteroids, non-sedating antihistamines, and ocular preparations (such as sodium cromoglicate or olopatadine eye drops) as first-line allergy treatments, as these are generally well tolerated with minimal systemic absorption

• Avoid self-medicating with NSAIDs such as ibuprofen; use only if advised by your prescriber with appropriate monitoring

• Avoid trimethoprim, co-trimoxazole, and combination cold remedies containing aspirin or ibuprofen; always tell any prescriber you are taking methotrexate before starting an antibiotic

• Attend all scheduled blood monitoring appointments, even if you feel well

• Report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)

With appropriate vigilance and good communication between patient and prescriber, the vast majority of people taking methotrexate can manage allergy symptoms safely and effectively without compromising their treatment.

Frequently Asked Questions